HRT demand boosts third-quarter sales at Warner Chilcott to $113m

WARNER CHILCOTT, the Northern drugmaker formerly called Galen, has reported a 13% rise in third-quarter sales.

The company said sales for the three months to the end of June had climbed by $13 million to $113 million, boosted by increased demand for its hormone replacement therapies (HRT), contraceptive pills and its Doryx acne cream. But sales of Sarafem, for premenstrual syndrome, fell 69% to just $6.7 million.

Chief executive Roger Boissonneault said the results show good growth, marginal improvement and cash generation in its continuing operations.